Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. (Nasdaq: VRDN) is a biopharmaceutical company that discovers and develops medicines for serious and rare diseases, with a focus on autoimmune conditions. Its pipeline includes veligrotug, an intravenous antibody targeting IGF-1R for thyroid eye disease (TED), and elegrobart, a… From the company’s description.
Over the twelve months to Sep 30, 2026, Viridian Therapeutics, Inc. reported revenue of $26.31M, down 62.8% from a year earlier, and a net loss of $453.58M. Operations used $341.50M in cash. In fiscal 2025, it reported revenue of $70.85M, up 23359.9% from fiscal 2024, and a net loss of $342.60M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Viridian Therapeutics, Inc. does
In the company’s own words
Viridian Therapeutics, Inc. (Nasdaq: VRDN) is a biopharmaceutical company that discovers and develops medicines for serious and rare diseases, with a focus on autoimmune conditions. Its pipeline includes veligrotug, an intravenous antibody targeting IGF-1R for thyroid eye disease (TED), and elegrobart, a longer-acting, subcutaneous IGF-1R antibody being studied for active and chronic TED. The company has submitted a U.S. biologics license application for veligrotug, which is under Priority Review, and a European marketing application; elegrobart is in global Phase 3 studies. Viridian also develops FcRn inhibitors VRDN-006 and VRDN-008 for potential use in autoimmune disorders, and a half-life-extended TSHR inhibitor candidate for TED and Graves’ disease. The company’s work spans antibody discovery and engineering, nonclinical and clinical development, manufacturing, and commercial planning. It is building sales, marketing, market-access, patient-services, and distribution capabilities in preparation for potential product launches. Viridian has worldwide commercialization rights to veligrotug and elegrobart, with specified regional exceptions.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1590750
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Viridian Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Viridian Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Viridian Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Viridian Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Viridian Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”